Life Science Investing Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Life Science Investing Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Life Science Investing Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Life Science Investing Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference
Life Science Investing High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Life Science Investing "LEQEMBI®" IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
Life Science Investing Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology Kidney Week 2025
Life Science Investing Health Canada Grants Authorization for "LEQEMBI®" for the Treatment of Early Alzheimer's Disease
Life Science Investing Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
Life Science Investing Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
Life Science Investing LEQEMBI® IQLIK Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
Life Science Investing LEQEMBI® IQLIK Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
Life Science Investing Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Life Science Investing "LEQEMBI®" IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
Homerun Resources Inc. Announces Listing of Its Shares on Tradegate Exchange in Germany Increasing European and International Market Liquidity
